Baxter and Coherus Biosciences Collaborate On Biosimilars
Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.
Baxter International and Coherus Biosciences, a pure-play biosimilars company. have entered into a collaboration to develop and commercialize a biosimilar of etanercept for Europe, Canada, Brazil, and certain other markets. Additionally, the agreement allows for the expansion of the collaboration to include another product.
Under the agreement, Baxter will make an upfront payment of $30 million. Coherus will conduct development, and Baxter will make payments of up to $216 million contingent upon the achievement of development and regulatory events. The agreement also allows for development and commercialization of an alternative biosimilar to etanercept, pending the outcome of clinical data.
Source: Baxter International
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
PostEra Expands Pfizer Partnership with AI Lab and ADC Collaborations
January 8th 2025The AI Lab was launched almost exactly three years ago and has produced several programs so far, at least one of which achieved its first scientific stage gate 40% faster than the teams originally forecasted.
